U.S. FDA Grants Orphan Drug Designation for Burzynski Research Institute’s Antineoplaston Treatment for Gliomas

Published: Dec 02, 2008

HOUSTON--(BUSINESS WIRE)--The Burzynski Research Institute, Inc. (BRI) today announced that its antineoplaston A10 and antineoplaston AS2-1 therapy (ANP) has been granted orphan drug designation by the U.S. Food and Drug Administration (“FDA”) for the treatment of gliomas. It is estimated that in 2008 more than 21,000 men and women in the U.S. will be diagnosed with this type of cancer, with prevalence estimated at approximately 84,000 cases.

Back to news